BioSpace News Archive

Business

Taysha Gene Therapies Announces Sponsored Genetic Testing for Giant Axonal Neuropathy (GAN) in Partnership with GeneDx as well as a Collaboration with Hereditary Neuropathy Foundation and Charcot-Marie-Tooth Association Centers of Excellence

Taysha Gene Therapies, Inc. today announced sponsored genetic testing for giant axonal neuropathy (GAN) in partnership with GeneDx, Inc.

October 13, 2021
·
9 min read
Biotech Bay

Vera Therapeutics to Present Phase 2a Data on Atacicept in IgA Nephropathy at the American Society of Nephrology Kidney Week 2021 Annual Meeting

Vera Therapeutics, Inc. announced today the upcoming presentation of clinical data for the Company’s lead product candidate, atacicept, from the Phase 2a JANUS clinical trial in patients with IgA nephropathy (IgAN).

October 13, 2021
·
1 min read
Biotech Beach

Progenity Announces Several Patents Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Ingestible Therapeutics Technologies

Progenity, Inc. announced today that the United States Patent and Trademark Office (USPTO) has issued four patents related to its ingestible technologies for delivery of therapeutics via the gastrointestinal (GI) tract.

October 13, 2021
·
7 min read
Business

Accuray to Report First Quarter Fiscal 2022 Financial Results on November 3, 2021

Accuray Incorporated (NASDAQ: ARAY) will report financial results for the first quarter of fiscal year 2022, ended September 30, 2021 , after the market close on Wednesday, November 3, 2021

October 13, 2021
·
1 min read
Drug Development

Apnimed Announces Positive Phase 2 Data (Study APC-004) Demonstrating Improvement in Measures of Obstructive Sleep Apnea and a Dose-Response with AD109, an Oral Pharmacologic Investigational Treatment for the Disease

Apnimed today announced positive data across multiple endpoints from its Phase 2 randomized, double-blind, placebo-controlled, crossover clinical trial (Study APC-004) evaluating the efficacy and safety of AD109 as a treatment for patients with mild to moderate OSA.

October 13, 2021
·
6 min read
Business

Oakland University welcomes new director of Eye Research Institute, founding director of OUWB Eye Research Center

Oakland University has welcomed Mohamed Al-Shabrawey as the new director of OU’s Eye Research Institute (ERI) and founding director of the Eye Research Center at Oakland University William Beaumont School of Medicine (OUWB).

October 13, 2021
·
2 min read
BioCapital

Inovalon to Host Virtual Client Congress October 18-19, 2021

Inovalon (Nasdaq: INOV), a leading provider of cloud-based platforms empowering data-driven healthcare, announced that its annual Client Congress will take place virtually from October 18-19, 2021.

October 13, 2021
·
2 min read
Genetown

Selecta Biosciences to Present New Data for the ImmTOR™ platform at the ESGCT 28th Annual Congress

Selecta Biosciences, Inc. (NASDAQ: SELB), today announced it will be presenting preclinical data in four posters highlighting its ImmTOR nanoparticle platform and its potential to safely enable repeat vector dosing in gene therapy patients at the 28th Annual Congress of the European Society of Gene & Cell Therapy

October 13, 2021
·
5 min read
Vaccitech to Present an Update on Its Chronic HBV Infection Immunotherapeutic Program at The World Vaccine Congress Europe

Vaccitech plc (NASDAQ: VACC), today announced that Tom Evans, M.D., Vaccitech’s Chief Scientific Officer will present an update on the Company’s chronic hepatitis B (CHB) immunotherapeutic Phase 1b/2a trial at The World Vaccine Congress Europe on October 21 in Barcelona, Spain.

October 13, 2021
·
4 min read
Drug Development

I-Mab Advances Late-stage Development of Its Differentiated CD38 Antibody Felzartamab (TJ202) in China

I-Mab (the “Company”) (NASDAQ: IMAB), today announced that it has completed the patient enrollment of the phase 3 clinical trial of human CD38 antibody felzartamab (also known as TJ202) in combination with lenalidomide as a second-line therapy in patients with multiple myeloma (MM).

October 13, 2021
·
6 min read